Abstract Number: 1418 • ACR Convergence 2021
Patient Reported Outcomes on Quality of Life in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
Background/Purpose: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are often overlapping inflammatory diseases that occur in people older than 50 years. Both diseases can…Abstract Number: 0466 • ACR Convergence 2021
Subclinical Large Vessel Vasculitis in Polymyalgia Rheumatica
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related diseases. PMR occurs in approximately 50 % of GCA patients1, however the frequency…Abstract Number: 0505 • ACR Convergence 2021
Risk of Venous and Arterial Thromboembolism in Patients with Giant Cell Arteritis And/or Polymyalgia Rheumatica: A Veterans Health Administration Population-Based Study in the United States
Background/Purpose: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are two chronic systemic inflammatory diseases that primarily affect elderly women. Both diseases can be complicated…Abstract Number: 0507 • ACR Convergence 2021
Tocilizumab in Patients with New Onset Polymyalgia Rheumatica (PMR-SPARE) – a Phase 2/3 Randomized Controlled Trial
Background/Purpose: PMR is the second most common inflammatory rheumatic disease of people aged 50 years or older. Glucocorticoid therapy is highly effective, but many patients…Abstract Number: 0653 • ACR Convergence 2021
Adherence to the 2015 ACR Guidelines for the Management of Polymyalgia Rheumatica and Screening for Osteoporosis at a Tertiary Care Medical Center
Background/Purpose: Since the first description of polymyalgia rheumatica (PMR) in the early 1950s, the ideal dose and duration of glucocorticoid therapy has varied. In 2015,…Abstract Number: 0952 • ACR Convergence 2021
Outcomes of COVID-19 Infection in Patients with Primary Systemic Vasculitis and Polymyalgia Rheumatica: Results from the COVID-19 Global Rheumatology Alliance Physician Registry
Background/Purpose: Patients with primary systemic vasculitis (PSV) and polymyalgia rheumatica (PMR) may be at high risk for poor COVID-19 outcomes due to the treatments used,…Abstract Number: 0131 • ACR Convergence 2020
Analysis of the Total Body Composition in a Cohort of Patients with Elderly Onset Arthritis
Background/Purpose: Inflammatory arthritis in the elderly leads to greater comorbidity than that of the young patients, however, there are few data on body composition in…Abstract Number: 0421 • ACR Convergence 2020
Polymyalgia Rheumatica Is Associated with Later Menopause: An Observational Study
Background/Purpose: Oestrogen exposure leads to an increase in peak bone mass whereas menopause is associated with rapid bone loss. Numerous studies have linked rheumatoid arthritis…Abstract Number: 0422 • ACR Convergence 2020
Frailty and Health-Related Quality of Life in Patients with Polymyalgia Rheumatica
Background/Purpose: Frailty is a syndrome characterized by an increased vulnerability to stressors. Frailty and pre-frailty have been reported in 10% and 44%of community dwelling elderly,…Abstract Number: 0510 • ACR Convergence 2020
Expression and Functional Activity of the Angiotensin II System in Temporal Artery Lesions from Patients with Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is a large and medium size-vessel granulomatous vasculitis that predominantly affects the aorta and its major branches. The renin-angiotensin-aldosterone system…Abstract Number: 0794 • ACR Convergence 2020
Peripheral Blood T and B Lymphocyte Subsets in Arthritis in the Elderly
Background/Purpose: Multiple lymphocyte subsets like T and B cells have been connected to joint infiltration and inflammation in rheumatoid arthritis (RA). Identification of leucocyte subsets…Abstract Number: 1580 • ACR Convergence 2020
Generalized Immune Activation in Structures Related to PMR or GCA on PET/CT Assessment Does Not Occur in Immune Checkpoint Inhibitor-Treated Patients Who Do Not Go on to Develop Rheumatic Immune-Related Adverse Events
Background/Purpose: The pathogenesis of rheumatic immune-related adverse events (irAEs) from checkpoint inhibitor cancer immunotherapy directed against programmed cell death protein 1 (PD-1) and programmed death…Abstract Number: 1934 • ACR Convergence 2020
What Is the Significance of Periarterial Temporal Small Vessel Inflammation (SVI) on Temporal Artery Biopsy (TAB) in the Diagnosis of Vasculitis? A Systematic Review and Meta-analysis
Background/Purpose: Isolated inflammation of small vessels including capillaries, venules and arterioles surrounding a normal temporal artery (SVI) in patients suspected of having giant cell arteritis…
- « Previous Page
- 1
- …
- 6
- 7
- 8